Workflow
Biotech Drugs
icon
Search documents
Bio-Path Holdings Achieves Third Pre-Clinical Milestone Confirming Potential of BP1001-A as Treatment for Obesity in Type 2 Diabetes Patients
Globenewswire· 2025-05-01 11:00
Core Insights - Bio-Path Holdings, Inc. has reported promising preclinical results for BP1001-A, indicating its potential to prevent insulin resistance in cells, particularly in the context of obesity and Type 2 diabetes [1][3][5] Group 1: BP1001-A Development - BP1001-A has shown the ability to rescue the decrease in AKT activity in liver cells, which is associated with palmitic acid treatment, suggesting its effectiveness in preventing insulin resistance [1][3] - The drug downregulates Grb2 expression, which is linked to improved insulin signaling in both muscle and liver cell models [3][5] - Bio-Path plans to conduct further preclinical testing using a mouse model to evaluate BP1001-A's impact on weight, insulin sensitivity, and glucose tolerance [4] Group 2: Mechanism of Action - BP1001-A targets the Grb2 protein to enhance insulin sensitivity and lower blood glucose levels in Type 2 diabetes patients [5] - The drug has demonstrated the ability to restore insulin signaling in C2C12 myoblasts, myotubes, and HepG2 liver cells treated with palmitic acid [3][5] Group 3: Future Plans - If preclinical testing is successful, Bio-Path anticipates filing an Investigational New Drug (IND) application in 2025 to initiate a Phase 1 clinical trial [4] - The company is also advancing other product candidates, including BP1002 and BP1003, targeting different proteins for various cancers and metabolic diseases [6]
Arvinas to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025
GlobeNewswire News Room· 2025-04-28 11:00
Company Overview - Arvinas, Inc. is a clinical-stage biotechnology company focused on developing a new class of drugs based on targeted protein degradation [3] - The company is headquartered in New Haven, Connecticut and aims to improve the lives of patients with debilitating and life-threatening diseases [3] Financial Results and Corporate Update - Management will review the first quarter 2025 financial results and provide a corporate update during a live webcast on May 1, 2025, at 8:00 a.m. ET [1] - The webcast will be accessible under "Events and Presentations" on the investor page of the Arvinas website, with a replay available afterward [2] Drug Development Pipeline - Arvinas is advancing multiple investigational drugs through clinical development programs, including: - Vepdegestrant, targeting the estrogen receptor for patients with locally advanced or metastatic ER+/HER2- breast cancer [3] - ARV-393, targeting BCL6 for relapsed/refractory non-Hodgkin Lymphoma [3] - ARV-102, targeting LRRK2 for neurodegenerative disorders [3] Technology Platform - The company utilizes its PROTAC® (PROteolysis Targeting Chimera) protein degrader platform to develop therapies that selectively degrade and remove disease-causing proteins [3]
Organovo Provides Update on Cash and Nasdaq Continued Listing Requirements
Globenewswire· 2025-04-02 12:05
Core Viewpoint - Organovo Holdings, Inc. reported preliminary unaudited cash and net cash utilization results for the fiscal year ending March 31, 2025, indicating a cash balance of approximately $11.3 million and net cash utilization of $2.0 - $2.2 million for the fourth quarter [1][2]. Financial Summary - The preliminary cash and cash equivalents balance as of March 31, 2025, was approximately $11.3 million [2]. - The net cash utilization during the fourth quarter from January 1, 2025, to March 31, 2025, was approximately $2.0 - $2.2 million [2]. Nasdaq Compliance Update - The company expects to meet all requirements for continued listing on the Nasdaq Capital Market, having closed above the $1.00 minimum bid price since March 21, 2025 [3]. - Nasdaq requires a minimum of 10 consecutive trading days where the stock closes at a minimum bid price of $1.00, which the company has achieved [3]. Future Milestone Payments - The company anticipates receiving a $5 million milestone payment within the next 12 months related to the start of a Phase 2 clinical trial for the FXR agonist recently sold [4]. - Future milestone payments associated with the FXR agonist could total up to $50 million, including the $5 million payment upon the commencement of the Phase 2 clinical trial [4]. Company Overview - Organovo is a clinical stage biotechnology company focused on developing drugs effective in three-dimensional (3D) human tissues for drug development [5]. - The company utilizes proprietary technology to create 3D human tissues that replicate key aspects of native human tissue composition, architecture, function, and disease [5].
Strategic update on the progress and development of Molecure's key clinical projects in 2024
Globenewswire· 2025-03-28 14:00
Core Insights - Molecure achieved significant milestones in 2024, focusing on the development of innovative therapies, particularly OATD-01 and OATD-02, and plans to accelerate research and development efforts [1][2] Clinical Development - The international KITE clinical trial for OATD-01, targeting pulmonary sarcoidosis, has commenced with several patients already randomized, and recruitment is expanding across five centers in the USA and soon in Europe [3][5] - OATD-01 is also under consideration for partnership discussions, with several dozen meetings held with potential partners in 2024 [4] - The KITE trial is expected to provide critical data on the CHIT1 protein, which may have implications for other diseases, including MASH, projected to exceed $25 billion by 2032 [4][6] - The Phase II clinical trial for OATD-01 has been initiated, and efforts are underway to develop it for MASH treatment in partnership [5] - OATD-02 is progressing in Phase I trials, with no dose-limiting toxicity observed, allowing for continued dose escalation [7] Financial Performance - Molecure raised approximately PLN 30 million (around $7.72 million) through stock issuance in 2024, which will support ongoing clinical trials and operational activities [8][21] - Operating revenues for 2024 were PLN 2.9 million, down from PLN 3.7 million in 2023, while operating costs slightly decreased to PLN 35.2 million [21] Research and Development - The mRNA-targeted drug platform has validated two therapeutic targets, with plans to select lead compounds for further development [12] - Collaboration with Avicenna Biosciences is ongoing to optimize lead compounds in the USP7 program using AI tools [10] - Molecure is focusing on optimizing its organizational structure, reducing discovery-phase programs from five to three to concentrate resources on promising clinical assets [5] Business Development - In 2024, Molecure participated in several major industry conferences, holding numerous meetings with potential partners and investors, indicating strong interest in its clinical and preclinical programs [13][14] - The company plans to continue engaging in industry events in 2025 to further its business development efforts [21]
Organovo Announces Close of the Sale of FXR Program to Eli Lilly and Company
Newsfilter· 2025-03-25 15:25
Core Insights - Organovo Holdings, Inc. has successfully closed the sale of its FXR program, including the lead asset FXR314, to Eli Lilly and Company on March 25, 2025 [1][2] Group 1: Transaction Details - Organovo will receive an upfront payment and future milestone payments as FXR314 achieves key regulatory and commercial milestones [2] - Eli Lilly is acquiring all commercial and intellectual property rights to Organovo's FXR program for worldwide development and will handle all future clinical development [2] Group 2: Company Overview - Organovo is a clinical stage biotechnology company focused on developing drugs that are effective in three-dimensional (3D) human tissues [3] - The company utilizes proprietary technology to create 3D human tissues that replicate essential aspects of native human tissue composition, architecture, function, and disease [3]